Related references
Note: Only part of the references are listed.Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
J. R. Brown et al.
LEUKEMIA (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial
Nancy L. Bartlett et al.
BLOOD (2018)
Chemotherapy Significantly Improves Survival for Patients with T1c-T2N0M0 Medullary Breast Cancer: 3739 Cases From the National Cancer Data Base
Alina M. Mateo et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant
A. Hamasy et al.
LEUKEMIA (2017)
Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
Gianantonio Rosti et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants
Sun Ku Lee et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Ibrutinib treatment improves T cell number and function in CLL patients
Meixiao Long et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
Jennifer A. Woyach et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment
D. Jones et al.
LEUKEMIA (2017)
A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers
Patrick F. Smith et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
SNS-062 demonstrates efficacy in chronic lymphocytic leukemia in vitro and inhibits C481S mutated Bruton tyrosine kinase
Catherine A. Fabian et al.
CANCER RESEARCH (2017)
Potential mechanisms of resistance to venetoclax and strategies to circumvent it
Stephen K. Tahir et al.
BMC CANCER (2017)
Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL
Sabah Kadri et al.
BLOOD ADVANCES (2017)
Acquired mutations associated with ibrutinib resistance in Waldenstrom macroglobulinemia
Lian Xu et al.
BLOOD (2017)
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia
Inhye E. Ahn et al.
BLOOD (2017)
Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations
Adam R. Johnson et al.
ACS CHEMICAL BIOLOGY (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein
Claudia Walliser et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Second-generation inhibitors of Bruton tyrosine kinase
Jingjing Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies
Meghan Campo et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
Jan A. Burger et al.
NATURE COMMUNICATIONS (2016)
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL
Shruti Sharma et al.
ONCOTARGET (2016)
Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations
Chenglin Wu et al.
ONCOTARGET (2016)
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
Preetesh Jain et al.
BLOOD (2015)
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
Dalia Ercan et al.
CLINICAL CANCER RESEARCH (2015)
Targeting neoplastic B cells and harnessing microenvironment: the double face of ibrutinib and idelalisib
Rossana Maffei et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H. Wilson et al.
NATURE MEDICINE (2015)
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Kenneth S. Thress et al.
NATURE MEDICINE (2015)
AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
J. A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
Kami J. Maddocks et al.
JAMA ONCOLOGY (2015)
Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma
Vicente Fresquet et al.
BLOOD (2014)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Irreversible kinase inhibitors gain traction
Katharine Sanderson
NATURE REVIEWS DRUG DISCOVERY (2013)
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias
J. E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A Hypermorphic Missense Mutation in PLCG2, Encoding Phospholipase Cγ2, Causes a Dominantly Inherited Autoinflammatory Disease with Immunodeficiency
Qing Zhou et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2012)
Targeting the B cell receptor pathway in chronic lymphocytic leukemia
Matthew S. Davids et al.
LEUKEMIA & LYMPHOMA (2012)
Cold Urticaria, Immunodeficiency, and Autoimmunity Related to PLCG2 Deletions
Michael J. Ombrello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
Sarah E. M. Herman et al.
BLOOD (2011)
The resurgence of covalent drugs
Juswinder Singh et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer
Kenichi Suda et al.
CLINICAL CANCER RESEARCH (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia
Meike Vogler et al.
BLOOD (2009)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
Identification of a Btk mutation in a dysgammaglobulinemic patient with reduced B cells:: XLA diagnosis or not?
Simona Graziani et al.
CLINICAL IMMUNOLOGY (2008)
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors
Marissa N. Balak et al.
CLINICAL CANCER RESEARCH (2006)
Dynamics of chronic myeloid leukaemia
F Michor et al.
NATURE (2005)
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations
S Branford et al.
BLOOD (2004)
Regulation of phospholipase C γ isoforms in haematopoietic cells -: Why one, not the other?
JI Wilde et al.
CELLULAR SIGNALLING (2001)
Share Paper
